Amphastar Pharmaceuticals, Inc. (AMPH) vs Cullinan Therapeutics, Inc. (CGEM)
A side-by-side comparison of Amphastar Pharmaceuticals, Inc. and Cullinan Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AMPH
Amphastar Pharmaceuticals, Inc.
$25.37HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
CGEM
Cullinan Therapeutics, Inc.
$16.04HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — AMPH vs CGEM
growth of $100 · dividends reinvested · last 6yAMPH +26.7% (+4.0%/yr)CGEM -46.4% (-9.9%/yr)AMPH compounded faster over this window
AMPH CGEM
AMPH vs CGEM: by the numbers
- •AMPH is the larger company ($1.12B vs $986M market cap).
- •AMPH is profitable (10.76% net margin) while CGEM runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | AMPH | CGEM |
|---|---|---|
| P/E ratio | 15.01 | N/A |
| Forward P/E | 8.54 | N/A |
| PEG ratio | 0.11 | N/A |
| P/S ratio | 1.53 | N/A |
| P/B ratio | 1.46 | 3.06 |
| EV / EBITDA | 8.82 | N/A |
| FCF yield | 13.67% | N/A |
Profitability
| Metric | AMPH | CGEM |
|---|---|---|
| Gross margin | 47.68% | 0.00% |
| Operating margin | 15.66% | 0.00% |
| Net margin | 10.76% | 0.00% |
| ROE | 10.23% | -63.62% |
| ROIC | 5.93% | -68.64% |
Growth (annualized)
| Metric | AMPH | CGEM |
|---|---|---|
| Revenue CAGR (5Y) | 13.71% | N/A |
| EPS CAGR (5Y) | 134.23% | N/A |
| FCF CAGR (5Y) | 23.90% | N/A |
| Total return CAGR (5Y) | 6.13% | -7.48% |
Frequently asked
- Is AMPH or CGEM more profitable?
- AMPH runs the higher net margin — AMPH at 10.76% versus CGEM at 0.00%.
- How have AMPH and CGEM total returns compared?
- Over the past 5 years, AMPH delivered 6.13% and CGEM delivered -7.48% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Amphastar Pharmaceuticals P/E ratioAmphastar Pharmaceuticals ROECullinan Therapeutics ROEAmphastar Pharmaceuticals operating marginCullinan Therapeutics operating marginAmphastar Pharmaceuticals revenue growthCullinan Therapeutics revenue growthAmphastar Pharmaceuticals free cash flowCullinan Therapeutics free cash flow
Amphastar Pharmaceuticals & Cullinan Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.